Today: 28 February 2026
Subscribe
Browse Category

NASDAQ:MGRX 13 November 2025 - 23 February 2026

Mangoceuticals stock slips before the bell after a 49% surge — what traders watch next for MGRX

Mangoceuticals stock slips before the bell after a 49% surge — what traders watch next for MGRX

Mangoceuticals shares fell about 4% to 51 cents in premarket trading Monday, easing after a 49% surge Friday that followed news of strong early sales for its $99-a-month testosterone therapy. Trading volume Friday spiked to 349 million shares. The company remains below Nasdaq’s $1 minimum bid requirement and has until August 3, 2026, to regain compliance.
23 February 2026
·
Mangoceuticals (MGRX) Soars on Eli Lilly and Novo Nordisk Deal as It Launches MangoRx Direct for Obesity Drugs

Mangoceuticals (MGRX) Soars on Eli Lilly and Novo Nordisk Deal as It Launches MangoRx Direct for Obesity Drugs

Mangoceuticals announced partnerships with Eli Lilly and Novo Nordisk to offer official access to Zepbound and Wegovy through new telehealth programs, MangoRx Direct and PeachesRx Direct. Membership costs $99 per month, with GLP‑1 drugs starting at $499 monthly, no insurance required. MGRX shares jumped over 25% pre-market before retreating. The company recently settled a lawsuit with Lilly and reported a $10.3 million net loss.
13 November 2025
····
Go toTop